Dilip Buildcon emerges as lowest bidder; stock gains
Dilip Buildcon emerges as lowest bidder; stock gains

Dilip Buildcon emerges as lowest bidder; stock gains

Chinmayee D Article rating: 3.0

The mineable reserve block is 1,091 million metric tonnes, which is to be exploited for a period of 25 years at a peak rated capacity of 50 million tonnes per annum.

Balkrishna Industries: Volume jumps 61 per cent QoQ in Q2FY21
Balkrishna Industries: Volume jumps 61 per cent QoQ in Q2FY21

Balkrishna Industries: Volume jumps 61 per cent QoQ in Q2FY21

Nidhi Jani Article rating: 4.7

On the volumes’ front, the company reported the highest-ever quarterly sales volume in Q2FY21. Besides, it registered a significant jump of 60.71 per cent QoQ to 61,224 MT in Q2FY21 vs 38,096 in Q1FY21.

Biocon share rises more than 4 per cent on receiving Rs 1,125 crore investment from Goldman Sachs
Biocon share rises more than 4 per cent on receiving Rs 1,125 crore investment from Goldman Sachs

Biocon share rises more than 4 per cent on receiving Rs 1,125 crore investment from Goldman Sachs

Ganesh V Article rating: 3.8

Biocon Ltd announced that the board of its subsidiary, Biocon Biologics Ltd has approved a capital injection of Rs 1,125 crore from Goldman Sachs on Saturday. Under the terms of the agreement, Goldman Sachs will be issued optionally convertible debentures at a post-money equity valuation of USD 3.94 billion.

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

Ganesh Pawar Article rating: 4.2

The market opened in green on November 09, 2020, overall volumes in futures & options currently stand at 1,90,93,884 contracts with a turnover of Rs. 14,51,060.02 crore.

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

Ganesh Pawar Article rating: 4.7

The market opened in green on November 09, 2020, overall volumes in futures & options currently stand at 1,90,93,884 contracts with a turnover of Rs. 14,51,060.02 crore.

IPO Analysis: Gland Pharma
IPO Analysis: Gland Pharma

IPO Analysis: Gland Pharma

Henil Shah Article rating: 3.5

Gland Pharma, a pharmaceutical company focussed on generic injectables, is hitting the primary capital market with its IPO today. Read on to find out if you should subscribe to the issue.

Early Diwali on D-Street: Nifty to aim its all-time high at 12,430; Gland Pharma opens for subscription today
Early Diwali on D-Street: Nifty to aim its all-time high at 12,430; Gland Pharma opens for subscription today

Early Diwali on D-Street: Nifty to aim its all-time high at 12,430; Gland Pharma opens for subscription today

Karan Dsij Article rating: 4.7

On Monday, the bull’s buying spree is showing no signs of abating as the early trends in SGX Nifty suggest that Nifty may open around its all-time high as it is trading up by 1.30 per cent at 12,424.50 levels. Certainly with the festive season i.e. Diwali being around the corner, the bulls are beaming with joy & celebrating with fireworks.

Nifty trend for Monday and stocks in news: Neogen Chemicals, Biocon, Adani Gas, Dilip Buildcon and Adani Enterprises.
Nifty trend for Monday and stocks in news: Neogen Chemicals, Biocon, Adani Gas, Dilip Buildcon and Adani Enterprises.

Nifty trend for Monday and stocks in news: Neogen Chemicals, Biocon, Adani Gas, Dilip Buildcon and Adani Enterprises.

Karan Dsij Article rating: 4.9

So, all the factors like the flag measure move target, all-time high levels, and the move away from its 20-DMA are indicating that we might move a per cent or two from here on, and then, we may consolidate. Interestingly, after trading above the long-term moving average i.e. 200-DMA for 79 days, the long-term moving average finally turned up, which is a positive sign. Further, Nifty outperformed Dow as Dollar has weakened. 

RSS
First19351936193719381940194219431944Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR